Vulvovaginal Candidiasis Treatment Market By Size, Share, Trends, Growth, Forecast 2028

Summary

Report Description

The Global Vulvovaginal Candidiasis Treatment Market is anticipated to witness an impressive growth during the forecast period. This can be ascribed to the growing development of new antifungal drugs and growing healthcare expenditure across the globe. Additionally, growing demand for the best treatment with low cost, along with growing geriatric population have significantly increased the demand for vulvovaginal candidiasis treatment across different parts of the globe. Additionally, increasing prevalence of chronic diseases like cancer, cardiovascular diseases, neurological diseases, and diabetes across the globe is further expected to increase the demand for vulvovaginal candidiasis treatment, thereby fuelling the market growth through 2028. Besides, growing awareness on maintaining hygiene and benefits of using new treatments with lower cost is further expected to support the vulvovaginal candidiasis treatment market during the forecast period. Furthermore, increasing usage of broad-spectrum antibiotic such as Fluconazole because of yeast infection is further expected to increase the demand for vulvovaginal candidiasis treatment, thereby supporting the market growth. It is the second most common type of vaginal infection after bacterial vaginal infections, in the United States. An estimated 1.4 million outpatient visits for vaginal candidiasis occur annually.

Growing Prevalence of Vaginal Candidiasis Is Driving the Market Growth

The growing prevalence of acute vulvovaginal candidiasis infection among the population is expected to grow the vulvovaginal candidiasis market over the future. Increasing number of research to find the prevalence of the VVC or RVVC is also expected to boost the segment growth. For instance, according to the article published in the Lancet Journal, Infectious diseases segment: 2018, globally, approximately 138 million women suffer from recurrent vulvovaginal candidiasis (relapse of acute vulvovaginal candidiasis, at least three times, within twelve months) and 3,871 per 100,000 women suffer from vulvovaginal candidiasis every year. Rapidly increasing chronic diseases across the globe, along with escalating demand for better treatment options and increasing number of hospital-acquired infections, are also propelling the demand for vulvovaginal candidiasis treatment. Furthermore, growing healthcare expenditure in the emerging countries, rising incidence of obesity and diabetes, growing government funding and rising initiatives by government and private organisations to spread awareness about the disease and its preventive measures are the factors that will expand the vaginal candidiasis treatment market.

Rising Research & Development Activities Will Drive the Market’s Growth

Increasing research and development on drugs and treatments of vulvovaginal candidiasis is predicted to boost growth of the global vulvovaginal candidiasis market during the forecast period. In April 2020, Scynexis Inc., revealed the promising results of Phase III trials which were conducted to check the effectiveness of an anti-fungal drug, Ibrexafungerp for treating VVCs. Also, major key players are submitting the application for new drug for treating vaginal infection to the regulatory bodies which will allow them to manufacture new drugs. These factors are expected to drive the market growth in the forecast period. For instance, in February 2021, SCYNEXIS, Inc. a biotechnology company focused on developing therapies and drugs for fungal infections partnered with Amplity Health, one of the global leaders in contract commercialization organization, to launch Brexafemme (Ibrexafungerp) in the United States.

Download Free Sample Report

Market Segmentation

The global vulvovaginal candidiasis treatment market can be segmented by drug class, by route of administration, by distribution channel and by region. Based on drug class, the market can be segmented into Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others. Based on route of administration, the market can be differentiated into Oral, Intravenous, Topical. Based on distribution channel, the market can be grouped into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United States dominated the global vulvovaginal candidiasis treatment market on account of growing usage of broad-spectrum antibiotic for yeast infection in the country.

Recent Development

In February 2021, the bio-tech company, Scynexis announced its agreement with the pharmaceutical company, Amplity Health to extend their support for the U.S. commercialization of BrexafemmeTM which is a brand name of Ibrexafungerp for vaginal infections.
In October 2019, the American pharmaceutical company, Mycovia Pharmaceuticals announced its collaboration with the Hungarian pharmaceutical company, Gedeon Richter to manufacture VT-1161 for treatment of vulvovaginal candidiasis.

Market Players

Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd., Scynexis, Inc., Grupo Ferrer Internacional, S.A., Pfizer, Inc., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc. are some of the leading players operating in the Global Vulvovaginal Candidiasis Treatment Market.

Attribute	Details
Base Year	2022
Historic Data	2018 – 2021
Estimated Year	2023
Forecast Period	2024 – 2028
Quantitative Units	Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	· By Drug Class · By Rout Of Administration · By Distribution Channel · By Region
Regional scope	North America; Europe; Asia Pacific; South America; Middle East & Africa
Country scope	United States; Canada; Mexico; France; Germany; United Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE
Key companies profiled	Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd., Scynexis, Inc., Grupo Ferrer Internacional, S.A., Pfizer, Inc., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc.
Customization scope	10% free report customization with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global vulvovaginal candidiasis treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Vulvovaginal Candidiasis Treatment Market, By Drug Class:

Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others

Vulvovaginal Candidiasis Treatment Market, By Route of Administration:

Oral
Intravenous
Topical

Vulvovaginal Candidiasis Treatment Market, By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Vulvovaginal Candidiasis Treatment Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ Germany

§ United Kingdom

§ Italy

§ Spain

o Asia Pacific

§ China

§ India

§ Japan

§ South Korea

§ Australia

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Vulvovaginal Candidiasis Treatment Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Vulvovaginal Candidiasis Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

5.1. Ongoing Clinical Trials

5.2. Completed Clinical Trials

5.3. Terminated Clinical Trials

5.4. Breakdown of Pipeline, By Development Phase

5.5. Breakdown of Pipeline, By Status

5.6. Breakdown of Pipeline, By Study Type

5.7. Breakdown of Pipeline, By Region

5.8. Clinical Trials Heat Map

6. Global Vulvovaginal Candidiasis Treatment Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others)

6.2.2. By Route of Administration (Oral, Intravenous, Topical)

6.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

6.2.4. By Region

6.2.5. By Company (2022)

6.3. Market Map

6.3.1. By Drug Class

6.3.2. By Route of Administration

6.3.3. By Distribution Channel

6.3.4. By Region

7. North America Vulvovaginal Candidiasis Treatment Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Drug Class

7.2.2. By Route of Administration

7.2.3. By Distribution Channel

7.2.4. By Country

7.3. North America: Country Analysis

7.3.1. United States Vulvovaginal Candidiasis Treatment Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Drug Class

7.3.1.2.2. By Route of Administration

7.3.1.2.3. By Distribution Channel

7.3.2. Canada Vulvovaginal Candidiasis Treatment Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Drug Class

7.3.2.2.2. By Route of Administration

7.3.2.2.3. By Distribution Channel

7.3.3. Mexico Vulvovaginal Candidiasis Treatment Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Drug Class

7.3.3.2.2. By Route of Administration

7.3.3.2.3. By Distribution Channel

8. Europe Vulvovaginal Candidiasis Treatment Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Drug Class

8.2.2. By Route of Administration

8.2.3. By Distribution Channel

8.2.4. By Country

8.3. Europe: Country Analysis

8.3.1. France Vulvovaginal Candidiasis Treatment Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Drug Class

8.3.1.2.2. By Route of Administration

8.3.1.2.3. By Distribution Channel

8.3.2. Germany Vulvovaginal Candidiasis Treatment Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Drug Class

8.3.2.2.2. By Route of Administration

8.3.2.2.3. By Distribution Channel

8.3.3. United Kingdom Vulvovaginal Candidiasis Treatment Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Drug Class

8.3.3.2.2. By Route of Administration

8.3.3.2.3. By Distribution Channel

8.3.4. Italy Vulvovaginal Candidiasis Treatment Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Drug Class

8.3.4.2.2. By Route of Administration

8.3.4.2.3. By Distribution Channel

8.3.5. Spain Vulvovaginal Candidiasis Treatment Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Drug Class

8.3.5.2.2. By Route of Administration

8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Vulvovaginal Candidiasis Treatment Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Drug Class

9.2.2. By Route of Administration

9.2.3. By Distribution Channel

9.2.4. By Country

9.3. Asia-Pacific: Country Analysis

9.3.1. China Vulvovaginal Candidiasis Treatment Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Drug Class

9.3.1.2.2. By Route of Administration

9.3.1.2.3. By Distribution Channel

9.3.2. India Vulvovaginal Candidiasis Treatment Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Drug Class

9.3.2.2.2. By Route of Administration

9.3.2.2.3. By Distribution Channel

9.3.3. Japan Vulvovaginal Candidiasis Treatment Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Drug Class

9.3.3.2.2. By Route of Administration

9.3.3.2.3. By Distribution Channel

9.3.4. South Korea Vulvovaginal Candidiasis Treatment Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Drug Class

9.3.4.2.2. By Route of Administration

9.3.4.2.3. By Distribution Channel

9.3.5. Australia Vulvovaginal Candidiasis Treatment Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Drug Class

9.3.5.2.2. By Route of Administration

9.3.5.2.3. By Distribution Channel

10. South America Vulvovaginal Candidiasis Treatment Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Drug Class

10.2.2. By Route of Administration

10.2.3. By Distribution Channel

10.2.4. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Vulvovaginal Candidiasis Treatment Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Drug Class

10.3.1.2.2. By Route of Administration

10.3.1.2.3. By Distribution Channel

10.3.2. Argentina Vulvovaginal Candidiasis Treatment Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Drug Class

10.3.2.2.2. By Route of Administration

10.3.2.2.3. By Distribution Channel

10.3.3. Colombia Vulvovaginal Candidiasis Treatment Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Drug Class

10.3.3.2.2. By Route of Administration

10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Outlook

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Drug Class

11.2.2. By Route of Administration

11.2.3. By Distribution Channel

11.2.4. By Country

11.3. MEA: Country Analysis

11.3.1. South Africa Vulvovaginal Candidiasis Treatment Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Drug Class

11.3.1.2.2. By Route of Administration

11.3.1.2.3. By Distribution Channel

11.3.2. Saudi Arabia Vulvovaginal Candidiasis Treatment Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value

11.3.2.2. Market Share & Forecast

11.3.2.2.1. By Drug Class

11.3.2.2.2. By Route of Administration

11.3.2.2.3. By Distribution Channel

11.3.3. UAE Vulvovaginal Candidiasis Treatment Market Outlook

11.3.3.1. Market Size & Forecast

11.3.3.1.1. By Value

11.3.3.2. Market Share & Forecast

11.3.3.2.1. By Drug Class

11.3.3.2.2. By Route of Administration

11.3.3.2.3. By Distribution Channel

12. Market Dynamics

12.1. Drivers

12.2. Challenges

13. Market Trends & Developments

13.1. Recent Developments

13.2. Mergers & Acquisitions

13.3. Product Launches

14. Competitive Landscape

14.1. Business Overview

14.2. Product Offerings

14.3. Recent Developments

14.4. Financials (As Reported)

14.5. Key Personnel

14.6. SWOT Analysis

14.6.1. Astellas Pharma Inc.

14.6.2. Mycovia Pharmaceuticals, Inc.

14.6.3. Basilea Pharmaceutica Ltd.

14.6.4. Scynexis, Inc.

14.6.5. Grupo Ferrer Internacional, S.A.

14.6.6. Pfizer, Inc.

14.6.7. Pacgen Life Science Corporation

14.6.8. NovaDigm Therapeutics, Inc.

14.6.9. Cidara Therapeutics, Inc.

14.6.10. Amplyx Pharmaceuticals Inc.

15. Strategic Recommendations

Figures and Tables

Frequently asked questions

What are the major drivers for the Global Vulvovaginal Candidiasis Treatment Market?

Increasing the usage of broad-spectrum antibiotics for yeast infection and growing geriatric population across the globe are some of the major factors driving the growth of global vulvovaginal candidiasis treatment market.

Who are the top players operating in the Global Vulvovaginal Candidiasis Treatment Market?

Which drug class type is expected to dominate the Global Vulvovaginal Candidiasis Treatment Market in the forecast period?

The clotrimazole is expected to dominate the global vulvovaginal candidiasis treatment market during the forecast period.

Which region is expected to account for the largest share in the Global Vulvovaginal Candidiasis Treatment Market?

North America region is expected to hold the largest share in the Global Vulvovaginal Candidiasis Treatment Market.

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

Vulvovaginal Candidiasis Treatment Market to be Dominated by Clotrimazole Drug Class Type through 2028

Dec, 2022

Increasing prevalence of chronic diseases is expected to drive the growth of global vulvovaginal candidiasis treatment in the forecast period, 2024-2028.

Buy Now